HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

618.706

+13.1722.18%

Number of Gainers:23

Number of Losers:8

Number of Flat:3

PE:- -

High:627.633

Open:605.584

Low:600.085

Close:605.533

Volume:128.59M

Turnover:3.83B

Market Cap:383.10B

Float Cap:341.05B

Loading ...

Cardiovalve Completes Target Study Enrollment for Ce Registration Study for Tricuspid Valve Replacement

THOMSON REUTERS

Promising CAR-T Trial Results and Major Buyback Could Be a Game Changer for CARsgen (SEHK:2171)

Simply Wall St.

RemeGen (SEHK:9995) Losses Widen 23.9% Annually, Profitability Forecasts Test Investor Optimism

Simply Wall St.

Everest Medicines (SEHK:1952): Valuation Insights Following Exclusive VIS-101 Ophthalmology Deal

Simply Wall St.

A Look at Akeso (SEHK:9926) Valuation Following Key Phase III HARMONi-6 Study Results

Simply Wall St.

InnoCare Pharma Insider Lowered Holding By 89% During Last Year

Simply Wall St.

BRII-B (02137) Grants 600,000 Share Options

New Stock Update | Alebund Pharmaceuticals Files for Hong Kong IPO, Core Product AP301 Completes Phase III Clinical Trial in China

Brii Biosciences Grants 600,000 Share Options to Advisory Board Member

ETF Daily: Positive News Fuels Optimism, Spotlight on Biotech Sector

Hong Kong Market Analysis: Hang Seng Dips Below Key Level Amid Month-End Pressure; Pharma Negotiations Drive Inflows

JPMorgan Increases Stake in Zai Lab (09688) by Approximately 611,105 Shares at HK$20.56 per Share

Innovative Drug Sector Surges: Fund Managers Analyze the Rally as Hong Kong Stock Connect Innovative Drug ETF (520880) Jumps 5.25%

ZYLOXTB (02190) Repurchased 50,000 Shares for HK$1.1874 Million on October 31

MABPHARM-B (02181): Dr. Zhang Yanyun Appointed as Lead Independent Non-Executive Director

Mabpharm Appoints Lead Independent Director and Updates Nomination Committee

Mabpharm Ltd. files director list with HKEX

Summit Therapeutics Reports Phase III Success for Ivonescimab in EGFR-Mutated NSCLC

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$1.93 Million on October 31

HK Short Interest Data as of October 31

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":618.7055,"timestamp":1761898110601,"preClose":605.53326,"halted":0,"volume":128593457,"delay":0,"changeRate":0.021753,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":13.172241,"latestTime":"10-31 16:00:00","open":605.58374,"high":627.6333,"low":600.08484,"amount":3826218301,"amplitude":0.045495,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1762133400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1761874200000,1761883200000],[1761886800000,1761897600000]],"pbRate":5.343409,"peRate":-44.036334,"turnoverRate":0.004666,"increases":23,"decrements":9,"flats":1,"marketCap":383100705664,"floatMarketCap":341050329040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":627.6333,"amplitude":0.045495,"preClose":605.53326,"low":600.08484,"pbRate":"5.343409","latestPrice":618.7055,"volume":128593457,"delay":0,"open":605.58374,"prevYearClose":331.1933,"prevWeekClose":617.318,"prevMonthClose":618.706,"prevQuarterClose":752.859,"fiveDayClose":615.593,"twentyDayClose":752.859,"sixtyDayClose":779.344,"secType":"PLATE","market":"HK","turnoverRate":0.004666,"peRate":-44.036334,"marketCap":383100705664,"floatMarketCap":341050329040,"timestamp":1761898110601,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":23,"down":8,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2580793264","title":"Cardiovalve Completes Target Study Enrollment for Ce Registration Study for Tricuspid Valve Replacement","url":"https://stock-news.laohu8.com/highlight/detail?id=2580793264","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580793264?lang=en_us&edition=fundamental","pubTime":"2025-11-02 03:13","pubTimestamp":1762024420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251101:nTUAB60Z1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02500","BK1574","BK1100","BK1583"],"gpt_icon":0},{"id":"2580424249","title":"Promising CAR-T Trial Results and Major Buyback Could Be a Game Changer for CARsgen (SEHK:2171)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580424249","media":"Simply Wall St.","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580424249?lang=en_us&edition=fundamental","pubTime":"2025-11-01 17:40","pubTimestamp":1761990028,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings recently announced encouraging results from clinical trials of its CAR-T therapies for solid tumors and plasma cell leukemia, while also commencing a share repurchase program covering up to 10% of issued share capital as mandated by its shareholders.\nThis combination of promising clinical advancements in immuno-oncology and capital management initiatives sets the company apart in a highly competitive sector.\nWe’ll explore how the initiation of a large share...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/promising-car-t-trial-results-and-major-buyback-could-be-a-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/promising-car-t-trial-results-and-major-buyback-could-be-a-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4022","BK1161","BK1574","02171","BK1585","CAR","BK1587","BK4230"],"gpt_icon":0},{"id":"2580425662","title":"RemeGen (SEHK:9995) Losses Widen 23.9% Annually, Profitability Forecasts Test Investor Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2580425662","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580425662?lang=en_us&edition=fundamental","pubTime":"2025-11-01 13:44","pubTimestamp":1761975888,"startTime":"0","endTime":"0","summary":"RemeGen (SEHK:9995) continues to operate at a loss, with annual net losses widening by an average of 23.9% over the past five years. While the company remains unprofitable, consensus forecasts point to a turnaround. Projections indicate RemeGen may reach profitability within three years, with earnings expected to surge 68.79% per year and revenue growth anticipated at 26.1% per year. With share price trading at HK$90, the focus is now on whether accelerating growth can justify a lofty...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-losses-widen-239-annually-profitability-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-losses-widen-239-annually-profitability-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09995","LU1969619763.USD","BK1583","BK1574","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2580442202","title":"Everest Medicines (SEHK:1952): Valuation Insights Following Exclusive VIS-101 Ophthalmology Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2580442202","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580442202?lang=en_us&edition=fundamental","pubTime":"2025-11-01 09:44","pubTimestamp":1761961491,"startTime":"0","endTime":"0","summary":"Everest Medicines (SEHK:1952) has secured exclusive rights to develop and commercialize VIS-101, a promising bifunctional treatment for eye conditions like wet AMD, across Greater China and parts of Asia. This strategic move underscores the company’s ambitions in ophthalmology and signals potential growth ahead.\nSee our latest analysis for Everest Medicines.\nEverest Medicines’ exclusive VIS-101 deal adds momentum to a year already marked by strong long-term performance. The company posted an...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-insights-following-excl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-insights-following-excl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK1583","MDCO","VIS","BK1574","01952","BK1161","BK4588"],"gpt_icon":0},{"id":"2580422044","title":"A Look at Akeso (SEHK:9926) Valuation Following Key Phase III HARMONi-6 Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2580422044","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580422044?lang=en_us&edition=fundamental","pubTime":"2025-11-01 09:35","pubTimestamp":1761960911,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) was in the spotlight after recently published Phase III HARMONi-6 study results showed its bispecific antibody, ivonescimab, plus chemotherapy significantly improved progression-free survival in advanced squamous NSCLC compared to current treatments.\nSee our latest analysis for Akeso.\nAkeso’s big clinical win comes after a year of remarkable momentum, with a year-to-date share price return of 93.5% and a 66.3% total shareholder return over the past twelve months. Excitement...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/a-look-at-akeso-sehk9926-valuation-following-key-phase-iii-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/a-look-at-akeso-sehk9926-valuation-following-key-phase-iii-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4533","LU0234572021.USD","BK4568","LU0289739699.SGD","LU0321505868.SGD","IE00BLSP4239.USD","BK4550","LU1883839398.USD","LU2476274308.USD","LU0306807586.USD","LU0225284248.USD","BK4581","LU0348784397.USD","LU2399975544.HKD","BK4134","IE00BLSP4452.SGD","LU0348783233.USD","LU1720050803.USD","LU0868494617.USD","LU1794554557.SGD","SGXZ57979304.SGD","LU0985481810.HKD","LU0634319403.HKD","LU0306806265.USD","LU0348825331.USD","SG9999001176.USD","LU0417516902.SGD","LU0417516571.SGD","LU1066053197.SGD","IE0002270589.USD","LU1894683264.USD","09926","SG9999002232.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348735423.USD","SG9999003800.SGD","BK4534","BK1574","BK4592","III","LU0561508036.HKD","IE00B19Z3581.USD","LU0456855351.SGD","LU1894683348.USD","LU0122379950.USD","BK4585","IE00B19Z3B42.SGD","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2580875446","title":"InnoCare Pharma Insider Lowered Holding By 89% During Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2580875446","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580875446?lang=en_us&edition=fundamental","pubTime":"2025-11-01 07:39","pubTimestamp":1761953940,"startTime":"0","endTime":"0","summary":"Insiders were net sellers of InnoCare Pharma Limited's ( HKG:9969 ) stock during the past year. That is, insiders sold...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-insider-lowered-holding-by-89-during-last-ye","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-insider-lowered-holding-by-89-during-last-ye","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"1121775711","title":"BRII-B (02137) Grants 600,000 Share Options","url":"https://stock-news.laohu8.com/highlight/detail?id=1121775711","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121775711?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:32","pubTimestamp":1761917541,"startTime":"0","endTime":"0","summary":"BRII-B (02137) announced that on October 31, 2025, the company granted 600,000 share options to grantees under the terms of its 2023 Share Option Scheme, subject to acceptance by the grantees. As of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137","BK1587","BK1161","BK1574"],"gpt_icon":0},{"id":"1148693798","title":"New Stock Update | Alebund Pharmaceuticals Files for Hong Kong IPO, Core Product AP301 Completes Phase III Clinical Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1148693798","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148693798?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:26","pubTimestamp":1761917183,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Co., Ltd. (\"Alebund Pharmaceuticals\") has submitted its listing application to the Hong Kong Stock Exchange's main board, with Jefferies, BofA Securities, and HTSC...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEXmain","BK4134","BK1161","III","159938","09939","BK1515","BK1574"],"gpt_icon":0},{"id":"2579462719","title":"Brii Biosciences Grants 600,000 Share Options to Advisory Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2579462719","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579462719?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:17","pubTimestamp":1761916641,"startTime":"0","endTime":"0","summary":"Brii Biosciences Ltd. has announced the grant of 600,000 share options to a member of its scientific advisory board under its 2023 Share Option Scheme. The options were granted on October 31, 2025, and are subject to acceptance by the grantee. No financial assistance was provided to facilitate the purchase of shares under this scheme. The company stated that the recipient has previously provided significant scientific and strategic advisory services to the group.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL9hMkjQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","BK1161","02137"],"gpt_icon":0},{"id":"1140655601","title":"ETF Daily: Positive News Fuels Optimism, Spotlight on Biotech Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1140655601","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140655601?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:11","pubTimestamp":1761916291,"startTime":"0","endTime":"0","summary":"Affected by overnight weakness in U.S. tech stocks, China's A-shares opened slightly lower and trended downward, with previously strong overseas-mapping sectors leading the decline. At the close, the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1574","FDN","BK1161","BK4588","BK4585","BK4550","159992"],"gpt_icon":0},{"id":"1161162331","title":"Hong Kong Market Analysis: Hang Seng Dips Below Key Level Amid Month-End Pressure; Pharma Negotiations Drive Inflows","url":"https://stock-news.laohu8.com/highlight/detail?id=1161162331","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161162331?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:44","pubTimestamp":1761914672,"startTime":"0","endTime":"0","summary":"【Market Overview】   Month-end volatility struck again as the Hang Seng Index fell 1.43%, breaching the 26,000-point threshold. The recent U.S.-China summit signaled a temporary pause in global tariff...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MHImain","LU0300738514.USD","BK1186","LU0049112450.USD","SG9999002950.SGD","LU1046422090.SGD","513600","03877","BK1535","MCHmain","SG9999001440.SGD","LU0300738605.USD","YANG","01919","BK1161","HSImain","01138","BK1505","BK1166","SG9999001093.SGD","BK4614","159938","LU0390135688.USD","HHImain","SG9999011746.SGD","02833","SG9999003461.SGD","02343","LU0390135506.SGD","LU1235295612.USD","BK1574","LU0390135332.USD","BK1103","09939","BK1515","SG9999014674.SGD","HSI"],"gpt_icon":0},{"id":"1177359765","title":"JPMorgan Increases Stake in Zai Lab (09688) by Approximately 611,105 Shares at HK$20.56 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1177359765","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177359765?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:26","pubTimestamp":1761913595,"startTime":"0","endTime":"0","summary":"According to the latest disclosure from the Hong Kong Stock Exchange, on October 27, JPMorgan increased its holdings in Zai Lab (09688) by 611,105 shares at an average price of HK$20.5592 per share,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","LU2237443622.USD","LU0320765489.SGD","LU0942090050.USD","IE00BFXG1179.USD","IE00B1BXHZ80.USD","LU0323591593.USD","LU0208291251.USD","LU0265550359.USD","LU1668664300.SGD","BK4585","IE00BYXW3230.USD","IE00BKDWB100.SGD","LU2756315664.SGD","IE00BLSP4239.USD","LU0976567544.SGD","LU0215105999.USD","LU0211331839.USD","LU2237443465.HKD","SG9999002224.SGD","LU0882574139.USD","LU2237443549.SGD","LU0640476718.USD","LU0048584097.USD","LU1914381329.SGD","BK4581","LU0868494617.USD","LU0868494708.USD","LU0251132253.USD","LU0820561909.HKD","LU0310799852.SGD","LU0070302665.USD","LU1064131342.USD","JPM","LU1629891620.HKD","BK4566","LU0203347892.USD","LU0267386448.USD","IE00BZ1G4Q59.USD","LU0345769128.USD","BK4534","LU0787776722.HKD","IE000M9KFDE8.USD","LU0345770308.USD","LU0345770993.USD","LU2023250504.SGD","LU0820561818.USD","LU0238689110.USD","LU1267930490.SGD","BK4550","IE00BWXC8680.SGD","BK4531","LU2488822045.USD","LU2552382132.HKD","LU1280957306.USD","LU2746668461.USD","IE00BKVL7J92.USD","BK4526","LU0256863811.USD","LU0106261372.USD","LU0203345920.USD","LU0971096721.USD","LU2237443978.SGD","LU0106831901.USD","LU1894683264.USD","LU0211326839.USD","LU1145028129.USD","LU1119994496.HKD","LU1988902786.USD","LU1363072403.SGD","LU2505996681.GBP","LU2552382058.USD","LU2357305700.SGD","LU2211815571.USD","LU0683600562.USD","BK4504","BK4533","LU1551013425.SGD","BK4207","LU1084165304.USD","LU0345769631.USD","LU1244550221.USD","BK1588","LU1244550494.USD","LU2236285917.USD","LU2746668974.SGD","IE0034235188.USD","LU1917777945.USD","LU0211326755.USD","LU1670627923.USD","BK1161","LU0943347566.SGD","LU1720051108.HKD","IE00BJTD4N35.SGD","LU2552382215.SGD","LU2430703178.SGD","SG9999002232.USD","IE00BBT3K403.USD","LU0265550946.USD","LU2430703251.USD","LU1720051017.SGD","LU2237443895.HKD","IE00BLSP4452.SGD","09688","LU2264538146.SGD","LU0417517546.SGD","IE00BDCRKT87.USD","LU0006306889.USD","LU1162221912.USD","LU2430703095.HKD","ZLAB","IE00BDRTCR15.USD","LU0211327993.USD","IE00B1XK9C88.USD","BK4548","LU2381873111.SGD","LU0496365809.HKD","LU1244550577.SGD","LU1261432733.SGD","LU2242649171.HKD","BK4139","LU2456880835.USD","LU1366192091.USD","IE00BJLML261.HKD","BK4588","LU2213496289.HKD","LU2237443382.USD","BK1574","LU2756315318.SGD","LU2592432038.USD","LU2106854487.HKD","LU0964807845.USD","IE00BN8TJ469.HKD","LU1032466523.USD","LU2417539215.USD","LU1894683348.USD","LU1496350502.SGD","IE00B3S45H60.SGD","IE00BJTD4V19.USD","LU2054465674.USD","LU0320765646.SGD","LU0689472784.USD","LU1496350171.SGD","LU1548497426.USD","LU1974910355.USD","LU0170899867.USD","IE00B775SV38.USD","LU1670628061.USD","LU1116320901.HKD","BK4516","LU2462157665.USD","LU2023250330.USD","LU2023250843.SGD","IE00BHPRN162.USD","LU0234572021.USD","LU2505996509.AUD","LU1116320737.USD","IE0034235295.USD","LU0149725797.USD","IE0034235303.USD","LU0820562030.AUD","LU1551013342.USD"],"gpt_icon":0},{"id":"1142230500","title":"Innovative Drug Sector Surges: Fund Managers Analyze the Rally as Hong Kong Stock Connect Innovative Drug ETF (520880) Jumps 5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142230500","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142230500?lang=en_us&edition=fundamental","pubTime":"2025-10-31 20:10","pubTimestamp":1761912629,"startTime":"0","endTime":"0","summary":"On the last trading day of October (October 31), the long-dormant innovative drug sector suddenly surged, with simultaneous momentum in both A-shares and Hong Kong markets. The Pharmaceutical ETF...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159992","BK1161","06978","520880"],"gpt_icon":0},{"id":"1190855468","title":"ZYLOXTB (02190) Repurchased 50,000 Shares for HK$1.1874 Million on October 31","url":"https://stock-news.laohu8.com/highlight/detail?id=1190855468","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190855468?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:16","pubTimestamp":1761909370,"startTime":"0","endTime":"0","summary":"ZYLOXTB (02190) announced that it repurchased 50,000 shares for approximately HK$1.1874 million on October 31, 2025.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1583","BK1587","BK1100","BK1574"],"gpt_icon":0},{"id":"1110631901","title":"MABPHARM-B (02181): Dr. Zhang Yanyun Appointed as Lead Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1110631901","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110631901?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:10","pubTimestamp":1761909021,"startTime":"0","endTime":"0","summary":"Effective October 31, 2025, MABPHARM-B (02181) announced the following changes: Dr. Qian Weizhu, an executive director, has been appointed as a member of the company's nomination committee. Mr. Tao...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02181","BK1574","BK1161"],"gpt_icon":0},{"id":"2579468020","title":"Mabpharm Appoints Lead Independent Director and Updates Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2579468020","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579468020?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:04","pubTimestamp":1761908692,"startTime":"0","endTime":"0","summary":"Mabpharm Ltd. has announced changes to its management structure effective October 31, 2025. Dr. Qian Weizhu, an executive director, has joined the nomination committee, while Mr. Tao Jing has stepped down from the same committee. Additionally, Dr. Zhang Yanyun, an independent non-executive director, has been designated as the lead independent non-executive director. The nomination committee now consists of Mr. Guo Liangzhong , Dr. Zhang Yanyun, and Dr. Qian Weizhu.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabpharm Ltd. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL7mF2mv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02181","BK1161","BK1574"],"gpt_icon":0},{"id":"2579633884","title":"Mabpharm Ltd. files director list with HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2579633884","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579633884?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:04","pubTimestamp":1761908676,"startTime":"0","endTime":"0","summary":"Mabpharm Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange. The Board comprises Executive Directors Dr. Wang Hao , Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng, and Dr. Qian Weizhu. Non-executive Directors include Mr. Jiao Shuge  and Mr. Cen Jialin. The Independent Non-executive Directors are Dr. Zhang Yanyun , Mr. Guo Liangzhong, Mr. Leung, Louis Ho Ming, and Dr. Tao Qian. The company has established three committees. The Audit Committee is chaired by Mr. Leung, Louis Ho Ming, with members Mr. Jiao Shuge and Mr. Guo Liangzhong. The Remuneration Committee is chaired by Dr. Zhang Yanyun, with Dr. Wang Hao and Mr. Guo Liangzhong as members. The Nomination Committee is chaired by Mr. Guo Liangzhong, with Dr. Qian Weizhu and Dr. Zhang Yanyun serving as members.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for info","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL80G0Xz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02181","BK1161","BK1574"],"gpt_icon":0},{"id":"2579746333","title":"Summit Therapeutics Reports Phase III Success for Ivonescimab in EGFR-Mutated NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2579746333","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579746333?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:00","pubTimestamp":1761908446,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc. has announced that data from the Phase III HARMONi-A trial, evaluating the investigational bispecific antibody ivonescimab in combination with chemotherapy versus chemotherapy alone, will be presented at the Annual Meeting of the Society for Immunotherapy of Cancer  on November 7, 2025. The HARMONi-A study, conducted in China and sponsored by Akeso, Inc., focused on patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer  who had progressed after EGFR tyrosine kinase inhibitor  treatment. The trial demonstrated a statistically significant overall survival benefit for the ivonescimab regimen compared to standard care. Ivonescimab has not been approved by regulatory authorities in Summit's license territories, including the United States and Europe.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL9L1lMc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","BK1161","LU1720050803.USD","LU0348784397.USD","LU0348735423.USD","LU0348766576.USD","LU0348767384.USD","BK1574","LU1961090484.USD","LU0348827113.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2476274308.USD","LU0348825331.USD","IE00B543WZ88.USD","BK4139","LU0417516902.SGD","IE00BPRC5H50.USD","LU0417516571.SGD","LU2399975544.HKD","SMMT","LU0634319403.HKD","LU0348783233.USD","LU0417516738.SGD","LU2488822045.USD","LU1794554557.SGD","LU2778985437.USD","LU0561508036.HKD","LU0540923850.HKD"],"gpt_icon":0},{"id":"1180873927","title":"ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$1.93 Million on October 31","url":"https://stock-news.laohu8.com/highlight/detail?id=1180873927","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180873927?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:58","pubTimestamp":1761908303,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that it repurchased 200,000 shares for approximately HK$1.93 million on October 31, 2025.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1161","BK1191","01672","BK1515"],"gpt_icon":0},{"id":"1154233358","title":"HK Short Interest Data as of October 31","url":"https://stock-news.laohu8.com/highlight/detail?id=1154233358","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154233358?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:32","pubTimestamp":1761906770,"startTime":"0","endTime":"0","summary":"As of October 24, the top three stocks with the highest short interest ratios were ZTE (00763), China Vanke (02202), and COSCO SHIP HOLD (01919), with short interest ratios of 15.82%, 15.47%, and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0797268264.HKD","LU0348735423.USD","IE00BVYPNP33.GBP","LU0345776255.USD","06060","BK1526","LU0630378429.USD","LU1235295612.USD","06865","LU0871576103.HKD","LU1831875114.USD","HK0000252160.HKD","LU0106252389.USD","SG9999004311.SGD","LU0211977185.USD","01276","LU1226287529.USD","IE00BGHQDM52.EUR","LU0345775950.USD","09992","SGXZ62798434.SGD","LU0244354667.USD","IE00BF5LJ272.USD","601318","BK1136","LU0882747503.HKD","06181","LU1813983027.USD","IE00BYV24P56.USD","LU1481107354.HKD","LU0039217434.USD","LU0049112450.USD","HK0000500386.USD","LU0315179316.USD","LU0456854461.SGD","HK0000306685.HKD","LU0856984785.SGD","BK1594","LU0165289439.USD","IE00BMCWC346.EUR","LU0096374516.USD","BK1618","LU0594300179.USD","SG9999003461.SGD","02202","LU0878005551.USD","LU0469268626.HKD","LU1023057109.AUD","LU1282649810.SGD","BK1149","LU1769817179.HKD","BK1529","IE00BVYPNQ40.USD","LU0880133367.SGD","LU0499858602.USD","LU0588545904.SGD","LU0417516902.SGD","BK1189","82318","SG9999002950.SGD","BK1198","IE0003895053.USD","BK1550","LU0588545730.USD","00909","LU0149721374.USD","LU1282648689.USD","LU2097828714.EUR","BK1109","01787","LU0819123356.HKD","LU0345780521.USD","LU0196878994.USD","BK1184","LU1251922891.USD","LU0266512127.USD","BK1619","LU0348767384.USD","LU1880383440.USD","LU0084288322.USD","03750","LU0043850808.USD","LU0106959298.USD","06821","IE00BZ08YR35.GBP","LU0348783233.USD","LU1720050803.USD","BK1127","LU0634319403.HKD","LU0314109678.HKD","BK1515","LU1880383366.USD","LU2476274720.SGD","PNGAY","LU2293587155.HKD","BK1191","LU0572944931.SGD","LU1807302812.USD","LU0488056044.USD","00853","BK1207","LU0791590937.USD","LU1051768304.USD","LU0501845795.SGD","LU0878004406.USD","LU0791591158.USD","LU0821914370.USD","LU0762540952.USD","LU0417516738.SGD","LU0588545490.SGD","BK1178","LU0823426480.USD","03800","BK1521","BK1555","LU1044875133.USD","LU0890818403.SGD","BK1175","SGXZ90724238.SGD","LU1328277881.USD","LU2153592121.USD","LU0320764599.SGD","LU0254981946.USD","BK1100","LU2097828474.EUR","LU2543165471.USD","LU0708995583.HKD","LU1188198961.HKD","LU0531971595.HKD","LU1303224171.USD","BK1538","LU0593848301.USD","LU0737861699.HKD","LU0348805143.USD","LU0067412154.USD","BK1240","LU0345780281.USD","LU0918141705.HKD","09969","PAImain","BK1535","LU0762541174.USD","02600","BK1607","SG9999001440.SGD","BK1610","HPAD.SI","LU0348788117.USD","LU2097828805.USD","LU0865486749.SGD","LU1770036033.HKD","LU0640798160.USD","LU0384037296.USD","BK1571","LU0048580855.USD","LU0348784397.USD","LU0181495838.USD","LU1282649067.USD","BK1116","LU0197773160.USD","LU1105468828.SGD","BK1585","LU0831093199.SGD","LU0499858438.USD","SGXZ86797644.SGD","LU0328353924.USD","LU0348783662.USD","SG9999004220.SGD","LU2039709279.SGD","LU1504937902.USD","SG9999002562.SGD","SG9999001069.SGD","02318","BK1103","LU1282649141.HKD","01171","BK1224","LU1044876610.USD","BK1117","00763","IE0034224299.USD","IE00BZ08YT58.USD","LU1366334651.USD","BK1507","LU2348774022.SGD","LU0164865239.USD","LU0228659784.USD","LU0828237940.HKD","BK1513","LU0173614495.USD","HK0000306701.USD","LU1993786604.SGD","LU2399975544.HKD","LU0348816934.USD","IE0008368742.USD","BK1169","LU0819121731.USD","02158","LU0417516571.SGD","BK1505","BK1516","LU0287142896.SGD","03145","HK0000320264.USD","02899","LU1211504680.USD","LU2778985437.USD","LU1642822792.SGD","LU0918141887.USD","LU0886674414.USD","IE00BZ08YS42.EUR","LU1048588211.SGD","01919","LU1960683339.HKD","LU0163747925.USD","LU0348827113.USD","BK1161","SG9999002828.SGD","LU0164880469.USD","LU0828237510.HKD","HK0000252152.HKD","LU0327786744.USD","01772","LU2097828557.USD","LU0605514214.HKD","SG9999006597.SGD","LU1046422090.SGD","BK1506","BK1592","LU0456827905.SGD","09606","000002","LU0630378692.HKD","SG9999002463.SGD","LU0370786039.SGD","LU0762542818.HKD","LU1051769294.HKD","BK1583","LU0049853897.USD","LU1961090484.USD","LU1770034418.SGD","BK1129","LU0611395673.USD","LU1719994722.HKD","BK1509","LU0540923850.HKD","LU0359202008.SGD","LU2476274308.USD","01877","SG9999014674.SGD","03993","LU0862451753.SGD","LU0588546209.SGD","HK0000320223.HKD","06682","BK1190","LU0650527681.SGD","BK1613","LU1366334578.USD","LU0348814723.USD","LU1115378108.SGD","LU0231483743.USD","LU0561508036.HKD","LU0061477393.USD","LU0651947912.USD","BK1617","BK1589","BK1227","LU0235996351.USD","LU0197773673.USD","LU0348825331.USD","LU2226246903.HKD","LU0140636845.USD","LU1769817096.USD","LU0307460666.USD","LU0054450605.USD","LU0266512473.USD","LU1224709979.USD","LU0326950275.SGD","LU0463099449.HKD","LU0051755006.USD","LU1044874839.SGD","LU1048596156.SGD","LU0072913022.USD","LU0228367735.SGD","LU1981816686.USD","LU0594300419.USD","BK1554","02050","LU1515016050.SGD","BK1518","BK1544","LU0359201612.USD","LU0348766576.USD","SG9999001051.SGD","LU0052750758.USD","LU0648948544.HKD","LU2097828631.EUR","LU0449515922.USD","LU0315178854.USD","LU1794554557.SGD","LU0164872284.USD","LU2488822045.USD","LU0651946864.USD","BK1568","LU0072462343.USD","02367","LU0359201885.HKD","01541","LU0823426308.USD","BK1574","BK1183"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":1,"totalSize":230,"code":"91000000","status":"200"}]}}